{
  "doc_id": "2013_LG_AIOM_Epatocarcinoma_W11_26.9.13",
  "created_date": "2013",
  "country": "IT",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "EP EP Coordinator: Scientifi Scientifi Estensori: Daniel Daniel ico: nco nco Trevisani",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Table of Contents",
      "text": "1. Epidemiology .................................. General General ............................................. Incidence Incidence ................................... Mortality Mortality ................................................. Survival Survival ...................... Prevalence Prevalence ........................prevention prevention .....................surveillance surveillance ............... 4. Diagnosis .............................................5 Stadium .......A. A.....................2 2 Child- Pugh B............... C C ................................................................treatments treatments .... therapies therapies ................ Follow-up Follow-up ...............................",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "recommendations recommendations *",
      "text": "using using SIGN** they they are",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "the the GRADE*** method (if any).",
      "text": "Recommendation Recommendation (2) Recommendation SIGN (1) Clinical (3) administration administration of",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "weak weak positive",
      "text": "effects. effects.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "letters letters (A;B;C;D).",
      "text": "individual individual studies****. the the recommendation; clinical clinical recommendation",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "assessed assessed 1++ applicable applicable to",
      "text": "or. or.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "A",
      "text": "of of 1+ includes includes 2++ size. size.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "B",
      "text": "evaluated evaluated 1++ or 1+ includes includes 2+ effect. effect.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "C",
      "text": "evaluated evaluated 2++ 4 4 evidence",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "D",
      "text": "evaluated evaluated 2+",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "question question (comparison, comparison, outcome); in some cases",
      "text": "symbol symbol √. an an intervention/procedural procedure.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "(3) THE THE RECOMMENDATION",
      "text": "graduated graduated , importance importance , on 4 levels: the the intervention/question question . contraindications contraindications . damage damage . pcs pcs . the the surgery/intervention intervention / own own values/The The intervention/benefit benefit &amp; intervention intervention (s) intervention/offered. offered.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "1 - > individual individual RCTs",
      "text": "1 ++ 1 1 + 1 1 - bias bias -> of of case/individual individual case/effect effect . bias bias -> the the intervention/3 3 - > 4 4 - > Expert opinion.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Notes:",
      "text": "* website website ** SIGN= Network Network *** GRADE= Evaluation Evaluation (of of algorithms).",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "1.1 General",
      "text": "North North (NO 41%, NE 68% residents residents monitored), Center Center (26%) South South (32%). codes codes include: - hepatocellular carcinoma (79% early early tumors); - Colangiocarcinoma (6%); - Carcinoma (5%); - Adenocarcinomas (4%); - malignant tumor (2%).",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "1.2 Incidence",
      "text": "about about 4% approximately approximately 3:carcinoma carcinoma (HCC) of of +17% and and +65% North North (-39% and and -19% in women) virus virus (HCV). virus virus (HBV) next next year'2012 2012 (+12%), then. then.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "1.3 Mortality",
      "text": "age age (7%), place place (8%) 1990s 1990s (-1.6%); decrease decrease (-1.3%/year) South South (000 000 inhabitants/in in females), North. North.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "1.4 Survival",
      "text": "was was 15% and and 12% years years (20%, 37% and 48% respectively). context. context.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "1.5 Prevalence",
      "text": "2. 2.2:diagnosis diagnosis ( 48% years, years, 77% within 5 years) is is 25% years years (132/vs vs 106) the the country: 43 and 37/South. South.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "and and prevention",
      "text": "approximately approximately 85% diseases diseases (hemochromatosis and alpha-1-antitripsin deficiency) cirrhosis cirrhosis are: high high (normal normal values). active active HCV+times. times.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "and and surveillance",
      "text": "age age (over 70-75 years) treatments8 treatments8 (Evidence level 2++). increase increase (about 6%) detection detection of",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "4. Diagnosis",
      "text": "way way (per per abdomen) in in 90% micronodule micronodule (imaging imaging techniques) macronodulus macronodulus (5 5 mm) parenchyma parenchyma (as as \"hypervascularisation arterial\" or \"wash-in\"), in in venous/parenchima parenchima (of of \"premature wash\" or wash-out\"). mm mm (rarely rarely recognized), between 20% and 50% about about 75% than than 90% cm cm (12) (evidence evidence 2+) RM RM and/HCC HCC (the the venous/late phase) contrast contrast (CEUS, contrasted ultrasound) than than 1% MRI MRI and/aspect aspect (hypervascularisation hypervascularisation and/us-out), the the architectural/nodles nodles (≤ 2 cm), aspect aspect (well well differentiated), markers markers [and and GS], 16 16 (Level of evidence); Pathology Pathology (AFPI) advanced advanced cores; 3 3 (see Table). dedicated17 dedicated17 (evidence evidence 4). test test (LGD) The The ≥ ultrasound ultrasound (of of cirrhosis) MRI MRI and/RM RM and/RM RM &amp;/condition. condition.",
      "start_page": 9,
      "end_page": 11
    },
    {
      "heading": "5.1 General",
      "text": "function function (Child-Pugh) neoplasm neoplasm (TNM) patients. patients.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "hepatopathic hepatopathic patient",
      "text": "INR INR (coagulation coagulation factors), the the intermediate/insufficiency insufficiency (hebro-renal syndrome).points points (Table Table 1). gravity, gravity, A-5-6 5-6 = class A, 7-8-9 = C18 C18 (evidence evidence 2++). than than 50% over over 35%. ostrogastroduodenoscopy ostrogastroduodenoscopy (EGDS) bleeding bleeding (to to eradication) 19,20 (evidence evidence 2+). decision. decision.",
      "start_page": 11,
      "end_page": 13
    },
    {
      "heading": "Stadium Stadium systems",
      "text": "Italian Italian Program). vascular vascular and/STADIUM STADIUM Child- Pugh Pugh (months) extraepathic A = early Single <Tot Tot <1.0mg/TOT TOT <1.0 mg/29 29 Tot<1.0mg /tot tot >all all <Large Large B=Any Any C=the the patient'grade. grade.",
      "start_page": 13,
      "end_page": 15
    },
    {
      "heading": "6.1 Introduction",
      "text": "25 25 (Evidence level 4).",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Child-Pugh Child-Pugh A",
      "text": "of of \"property\" survival survival (75-80% to 5 years) malignancies malignancies ≤ cm26 cm26 (Lives) with with Markov'transplantability29-31 transplantability29-31 (level level 3). the the \"Milan\" criteria (of of nodules) patients30 patients30 (Level Level 3). the the \"down-staging\" 33 33 (evidence evidence 3). etc. etc., nodule nodule (2-3 cm) of 60-70% exceeding exceeding 2-3%37-40 (Highlight level 3). hypertension hypertension (plateletic count < 100,000/esophageal esophageal types) anatomical anatomical (2 2 cm) patients41 patients41 (Evidence level 2-). risk risk (gallbladder, gallbladder, bile). alcoholization alcoholization (PEI) 44 44 (Evidence level 1-), a a 10-15% HCC HCC ≤ surgery surgery (do do so; size size (>5 cm), chemoembolism chemoembolism (TACE) nodules nodules (>3) , metalysis47 metalysis47 (Taculum level 1+) about about 2% procedures procedures (with with bilobari) Bilirubinaemia > 3 mg/Status Status ≥ failure failure (creatinine ≥ 30 mg/dL) __MEDTERM0_ __MEDTERM0_ (Viewability Level 1+). with with −placebo placebo (SHARP study) survival survival (2 2 months; HR = 0.52; CI = 0.32-0,85)survival survival (survival survival (hypertension. hypertension.",
      "start_page": 15,
      "end_page": 19
    },
    {
      "heading": "Child-Pugh Child-Pugh B",
      "text": "transplantation57 transplantation57 (evidence evidence 2++). Milan Milan (downstaging downstaging protocols) 33 33 (evidence evidence 3). factors factors (Table 5). this this patient'B B √ cases. cases.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Child-Pugh Child-Pugh C",
      "text": "failure failure (Child-Pough C)",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Combined Combined treatments",
      "text": "treatments treatments (TACE + percutaneous ablation) treatments61 treatments61 (evidence evidence 1+). lesion. lesion.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Adjuvant Adjuvant therapies",
      "text": "to to 70% 62 62 (evidence evidence 1+). HCC63 HCC63 (1 1 +). considered. considered.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "6 6 Follow-up",
      "text": "thereafter. thereafter.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Advanced Advanced HCC",
      "text": "thrombosis thrombosis and/__MEDTERM0_. __MEDTERM0_.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Child-Pugh Child-Pugh A",
      "text": "patients patients (no 0-0-0-stage stage HCC) III III studies: treatment treatment (previous previous treatments), function function (Child-Pugh A). and and five-trial trial (world world (Israel, Israel, Australia), Asia Asia (and and Korea). the the patient'studies studies (years years (and and 5; with with __%function function (Child-Pough A) dose dose (a a day), level level (other other day): 1 1 - 2 2 - 1st occurrence - 2nd occurrence - 3rd occurrence - 4th occurrence - 3 3 - 1° occurrence - 2° occurrence - 1. 1.",
      "start_page": 21,
      "end_page": 23
    },
    {
      "heading": "Child-Pugh Child-Pugh B",
      "text": "only only (Child-Pugh Class A). study study (Feature Level 2++), 67 67 (Feature level 2-) . events events (hepatic hepatic functionality) with with @time. time.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Child-Pugh Child-Pugh C",
      "text": "function function (Child-Pugh C). patients. patients.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "treatments. treatments.",
      "text": "treatments treatments (and and anti-androgenic) tamoxifen tamoxifen (40 mg/day) therapy therapy alone; patients68 patients68 (Live 1+ medicinal products). study69 study69 (Level 1+) conducted47 conducted47 (evidence evidence 1+). Asia Asia (and and Thailand) for for progression- free survival (HR HR = p p < 0.001) survival survival (H H = p p = 0.07), advanced advanced and/50 50 mg/with with HCC: more than 90% the the remaining; a a liver; 89% patients patients had",
      "start_page": 24,
      "end_page": 25
    },
    {
      "heading": "non-cirrhotic non-cirrhotic patients",
      "text": "the the resection; 8 8 - 80%. 64 64 (evidence evidence 1+).",
      "start_page": 25,
      "end_page": 26
    },
    {
      "heading": "7. Algor",
      "text": "CCH CCH id",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "oihcsir",
      "text": "a etneizap led",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "omtiroglA",
      "text": "NOM NOM MA",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": ":ocytorric etneizap",
      "text": ")acytape",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "omtyrogla",
      "text": "etneizap ni",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "idev noc",
      "text": "eS eS",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ocythape",
      "text": "id aznedivE",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "oludonisem",
      "text": "acytape",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "swallow",
      "text": "B",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "acinorc",
      "text": "3F ≥",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "noc",
      "text": "isonghaiD isonghaiD > isofangaid isongeiDaispoiBocifargetsargeni-hsawasoefasafnini-HsaW* isogaiDocifargotsartonoc CCH id*nocgnimite nocgnimite nocgni",
      "start_page": 26,
      "end_page": 29
    },
    {
      "heading": "isorric",
      "text": "and",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "otatimil",
      "text": "CCH AhguP-dlihC",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "etneizap",
      "text": "led",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "omtiroglA",
      "text": "ATOCARCINOMA",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "noc",
      "text": "id",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "or",
      "text": "mc li )5 5 ≤ id 3",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "ien .elatropenoisnetrepiaznes",
      "text": "id",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "eolognisoludon",
      "text": "CCH",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "eralocsav",
      "text": "and",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "noc",
      "text": "I* e e otagef",
      "start_page": 29,
      "end_page": 30
    },
    {
      "heading": "omtiroglA",
      "text": "acitape acitape noc)atatimil,itanoizeles)IEP and",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "olognis",
      "text": "ocinilC ocinilC ,enoizalbABhguP-dlihC enoizalbABhguP-dlihC :.se( itneizap( oludon)aznes aznes )ECAT ECAT itneizap( 5 5 ≤ id 3",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "iludon iludon ≤",
      "text": "artneiR artneiR oludon( EPATOC EPATOC la",
      "start_page": 30,
      "end_page": 31
    },
    {
      "heading": "otatimil",
      "text": "CCH ChguP-dlihC",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "noc",
      "text": "etneizap",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "isorric",
      "text": "led",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "otnemattarT",
      "text": "and",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "omtiroglA",
      "text": "CAR RCIN NOMA",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "otroppus",
      "text": "id",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "aipareTonaliM",
      "text": "NON NON iretirc",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "otroppus",
      "text": "id aipareT",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "not id",
      "text": "e.g. elibiggel",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "mc li ) mc",
      "text": "5 5 ≤ id 3",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "heroiggam",
      "text": "ien",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "onif",
      "text": "ChguP-dlihC",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "otatimil enoisavni acipocsorcam",
      "text": "CCH aznes acitape",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "eralocsav",
      "text": "and",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "isorricC",
      "text": "etneizap etneizap led",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "omtiroglA",
      "text": "BhguP BhguP -dlihihC isorric isorriC",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "otaznava) isatsatem",
      "text": "èlocsav CCH o/e",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "noc enoisavni( acipocsorcam",
      "text": "adnoces adnoces id",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "Id otnemillafbinefaroS otremillaf",
      "text": "otnemattart otnemattart opod",
      "start_page": 32,
      "end_page": 33
    },
    {
      "heading": "pu-wolloF",
      "text": "otnemattart otnemattart opod",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "pu-wolloF",
      "text": "OMA OMA .otsartnoc otsartnoc ,o o otnaiparT",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "GRADE GRADE methodology",
      "text": "QUESITE 1: cirrhosis cirrhosis (max Child-Pugh B), vs vs TACE? RECOMMENDATION: patients patients (max Children B) TACE TACE with",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Reasons/sheet sheet Benefit/Danno:",
      "text": "to to TACE's with",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Quality of Evidence",
      "text": "following following reasons: compared. compared.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "of of evidence: MODERATA",
      "text": "online online appendix: characteristics. characteristics.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "9 Bibliography",
      "text": "et et al: hepatitis hepatitis VVulcents: Inst Inst 101:Hadengue Hadengue A: Med Med 101:Yang Yang BH; Tang ZY: oncol oncol 130:et et at: et et al: in in cirrhosis: Hepatology Hepatology 47:hepatocellular hepatocellular carcinoma: 435 435 patients: Program Program (CLIP) investigators. Hepatology 28:Bruix Bruix J: Julular Julular cancer: Disease Disease 19:et et al: HCC HCC patient: Onc Onc 24(S2):et et Al: et et al: Donor Donor Surgery: transplantation transplantation (LDLT). Liver Transpl 12:et et all: transplantation transplantation 134:Bruix Bruix J: Suppl Suppl 1:et et Al: et et al: Hepatology Hepatology 35:Bruix Bruix J: Gluud Gluud C: Transarterial (chemo) Syst Syst Rev:et et Al: et et al: Oncol Oncol 9:and and al: et et all: GIDEON GIDEON (with with __MEDTERM1_) Pract Pract 66:et et Al: et et al: Oncol Oncol 23:70. 70.",
      "start_page": 35,
      "end_page": 39
    },
    {
      "heading": "Date: 2012-06-28",
      "text": "Question: Chemoembolism Chemoembolism (TACE) bead bead (DC Bead) cancer cancer (HCC)? Settings: unresectable unresectable HCC",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "patients patients Effect",
      "text": "Chemoembolism Chemoembolism (TACE) bead bead (DC (95% CI) Bead)",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Overall Survival (Lammer 2010) (6 6 months; appointed with: observation of death)",
      "text": "no",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "100 100 +",
      "text": "none none (88 ./ 69 %3 (8 7/ .1 40 %8 (0 3. .5 31) t o (to to CRITICAL",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "i i s) ) 2 7 m) MODERATE",
      "text": "bias",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Overall Survival (Sacco 2011) (2 2 months; established with: observation of death)",
      "text": "100 100 \\Ο",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "none none (27 1/ 3 23 (27 0/ .3 64 (20 .. 64 t) o (rw rw e) e r CRITICAL",
      "text": "s s %) % ) MODERATE MODERATE bias",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Rate Rate (Lammer 2010)",
      "text": "more more per",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "ss ss (65 39 ./ 49 %3 (5 56 1/ 1 90 %w0 w0 (om om 92)",
      "text": "none none (0 1. .9 56 )t or CRITICAL",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "i i s) ) 2 2 MODERATE",
      "text": "bias more)",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Complication rate (Lammer 2010)2 (6 6 months; assigned with: Post treatment Complication)",
      "text": "per per 100",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "1 none (0 1. .5 34 ) t o (rw rw e) e r IMPORTANT",
      "text": "n n ) ) HIGH HIGH bias",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Rate Rate (Sack 2011) (assessed with: EASL Criteria)",
      "text": "100 100 +",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "i i s) ) 8 2 MODERATE",
      "text": "rate rate (Sack 2011)2 (6 6 months; appointed with: Post treatment Complication) per per 100",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "n n ) ) 9 3 HIGH",
      "text": "deterioration deterioration (Lammer 2010) (6 6 months; measured with: ALT increase; lower lower values) 50 50 ■ iu iu os",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "108 108 - 5r 5r l( 3 3 e9)t 3o IMPORTANT",
      "text": "deterioration deterioration (Sacco 2011) (6 6 months; measured with: ALT increase; lower lower values) os os (re re ) r",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "34 34 - IMPORTANT",
      "text": "toxicity toxicity (Lammer 2010) (follow-up median 6; appointed with: NCIC TOX Grade) no",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "os os (22 32 ./ 79 %3 (3 12 6/.1 29 %8",
      "text": "1 none (10 .. 25 t) or (rw rw e) p p n) toxicity toxicity (Saccus 2011) - Sample Sample size",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "for for AST",
      "text": "significative significative (P < .007) DEB DEB chemomembolism",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "heading heading <question question (comparison, comparison, outcome); in some cases>",
      "text": "Row 1: Clinic recommendation (2) (clinical recommendation) Row 2: (recommendation) Recommendative (s) Row 3: (c) SIGN (1) Clinical (3) (cyl) Row 4: (d) effects. effects.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading <question question (comparison, comparison, outcome); in some cases>",
      "text": "Row 1: assessed assessed 1++ Row Row 2:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading <question question (comparison, comparison, outcome); in some cases>",
      "text": "Row 1: includes includes 2++ Row Row 2: size. size.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading <Note:>",
      "text": "Row 1: \"the the procedure\": \"Row 2: \"Recommendation\": 'Clinical': \"Forte-positive\": the the intervention/question. question. \"Row Row 5: the the surgery/question. question.\" \"the the procedure/own own values/preferences. Row 6: Negative Weak\" the the operation/procidurement concerned. \"Negative\": harm. harm.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <Note:>",
      "text": "Row 1: 1 - >\"RCT-Row RCT-Row 2: 1 ++\"risk. risk.\"Row 3: 1 +\"Row Row 4: 1 -\"risk risk -> Raw Raw 5: 2 - > \"of of case/individual individual studies\" Row 6: \"caso/control or cohort\" Row 7: 2 + \"effect. effect.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <and and surveillance>",
      "text": "Row 1: \"Clinical recommendation\" \"Row 2: \"Recommendation\" \"Recomendation\"\" Row 3: \"SIGN\" \"clinic\" \"Row 4: \"B B infection\" HCC. HCC.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading <and and surveillance> (from previous page)",
      "text": "Row 1: \"Clinical recommendation\" Row 2: \"Recommendation\" Row 3: \"SIGN\" Clinic \"Row 4: \"HCC. HCC. \"Weak positive\" Row 5: \"B\"L\" the the cost/alone. alone.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "heading heading <hepatopathic hepatopathic patient>",
      "text": "==References===External links==* Official website",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Stage Stage systems>",
      "text": "Row 1: \"Grade of\" Clinical Recommendation \"Strength of\" Row 2: \"Recommendations\" Recommending \"Row 3: \"SIGN\" Clinic \"Raw 4: \"B\"cirrhosis. cirrhosis. \"Strong positive\" Row 5: \"B\") with with \"HCC\" esophagogastrodudenoscopy esophagogastrodudenoscopy (EGDS) treatment. treatment. \"EGDS\" of of \"HDC\" occurred. occurred. \"Viface-related\" blockers blockers and/binding. binding.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Stage Stage systems>",
      "text": "Row 1: \"Score\" (s) \"1\" = \"2\") \" Row 2: Total Bilirubin (s):<2 mg/dl\" -2-3 mg/dl\" -3 mg/ dl\" -5 mg/ dl\" Row 3: time time (s), <1.7\" 7-2. 7-2.3\" -3,\" Inr >2.3\" Row 4: Albumina (s)...\">3.5 gr/dl[8 8 gr/dL\" [<2.8 g/dl] ] Row 5: Clinical Ascites (well well controlled) \"Moderate/severa\" -6: Hepatic Encephalopathy (six) \"Assent\" -2.8 gr/D\" -7\" Moderata/sevena\"",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Stage Stage systems> (from previous page)",
      "text": "Row 1: PARAMETRO-PUNTEGGIO-Row 2: •0 •1 •2 •\" Row 3: Child-Pugh •A •B •C •Row 4: tumor tumor •Unbodyal and ≤50% neoplasm neoplasm •Multimodular and ≤ 50% neoplasia neoplasia •Massive or > 50% cancer cancer • Row 5: Thrombosis portal •Assent •Now 6: Alphafetoprotein Alphafetoprotein •< 400 ng/ml •",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <Stage Stage systems> (from previous page)",
      "text": "Row 1: CLIP score...Middle survival (months) Row 2: 0...\"4\"5\" Row 3: 1\"28.7\" Row 4: 2\"15.2\" Row 5: 3\"7\"0\" Row 6: 4-6\"3.4\"",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <Stage Stage systems> (from previous page)",
      "text": "Row 1: STADIO/TUMORE (months) Row 2: A = early • Row 3: A0 • Single <2 cm • Tot Tot <1.0mg/dl • row 4: A1 •SingoloA •0 ♪Byl Byl Tot<1.0mg / dl •43 Row 5: A2 •Single A • 0 •No •Ipert portal. • Bil tot <1.0mg/d • 29 •Row 6: A3 • Singoloa •NO • Hypert portal; • Bill Tot • 1.0mg/Dl •25 • Now 7: A4 •all all <3 cm A-B",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <Stage Stage systems> (from previous page)",
      "text": "Row 1: Row Class 2: Child- Row 3: Pugh",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <Stage Stage systems> (from previous page)",
      "text": "Row 1: Survival Row 2: Median Row 3: (months)",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <Stage Stage systems> (from previous page)",
      "text": "Row 1: Elements Row 2: Additional",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A>",
      "text": "Row 1: \"Clinical recommendation\" = \"Row 2: \"Recommendation\": \"Raw 3: \"SIGN\" = Clinic\" = ...\"Row 4: \"the the patient'cirrhosis cirrhosis (score, score, BCLC).",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (from previous page)",
      "text": "Row 1: Row Row 2: Bilirubinaemia Bilirubinaemia > 3 mg/Status Status ≥ insufficiency insufficiency (creatin ≥ 2 mg/clearance clearance < 30 mg/ dl) Thrombosis Thrombosis portale",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (from previous page)",
      "text": "Row 1: \"Global Quality\" &amp; \"Clinical Recommendation\" &gt; Row 2: \"Recommendations\" &lt; Row 3: \"GRADE\" & #Row 4: \"Moderata\" &quot; patients patients (max Child B) used used * date date about",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh B>",
      "text": "==References===External links==* Official website* http://www.interpol.int/en/notice/search/en_en/index_en.htm",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "heading heading <Combined Combined treatments>",
      "text": "Row 1: Clinical Recommendation (Clinic Recommending (Civil Recommended) Row 2: \"Recommendations\" (Recommmentation) \" Row 3: \"SIGN\" (clinic) \"Row 4: \"Percutaneous Ablative Treatments\" transplantable. transplantable. \"Strong Positive\" (Row 5): \"B\"expected. expected. √ center. center.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A>",
      "text": "Row 1: \"Clinical recommendation\" \"Row 2: \"Recommendation\" \"Recomendation\"\" Row 3: \"SIGN\" \"Cyllinic\" \"Row 4: \"A\"considered. considered.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A>",
      "text": "Row 1: \"Clinical recommendation\" Row 2: \"Recommendation\" Row 3: \"SIGN\" Clinic \"Row 4: \"D\"thereafter. thereafter.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (from previous page)",
      "text": "Row 1: \"Clinical recommendation\": \"Recommendation\" = \"Recommandation\" + \"Row 3: \"SIGN\" + Clinic\" +\"\" Row 4: \"A\" = function function (Child-Pugh A), sorafenib. sorafenib.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (from previous page)",
      "text": "Row 1: Full dose • diet diet • Row 2: First reduction • day day • row 3: Second reduction − days days •",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (from previous page)",
      "text": "I'1st-century 1st-century treatment: 2nd-center conversion: 3rd-centered transition: 5th-centecent change: 5°-centity change: 4th-point change: 6th-off change: 7th-grad change: 9th-grade change: 8th-level change: 10th-time change: 11th-degree change: 13th-longer change: 15th-round change: 14th-range change: 12th-to-day change: 16th-year change: 17th-second-grade modification: 5nd-grade adjustment: 5rd-grade amendment: 5 years-old change: 0-1st-mile change: - 5th; 5th dose change: 3th-row change: 20th-five-grade alteration: 5 months-grade reduction: 5h1st-grade decrease: 5x change: the the 0-0st-point 0st-point improvement: 5X-grade shift change: from from 0-1nd-point reduction: 4nd-degree reduction: 3nd-level reduction: 2rd-point rotation reduction: 6nd-dose reduction: 7nd-shift reduction - 2nd",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 1)",
      "text": "Row 1: •Row Row 2: • Diarrhea",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 1)",
      "text": "Row 1: ... Cutaneous toxicity",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 1)",
      "text": "Row 1: Other non-haematol toxicity",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 2)",
      "text": "Row 1: Row Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 3)",
      "text": "Row 1: Row Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 4)",
      "text": "Row 1: Action Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 5)",
      "text": "Row 1: ne...Mo Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 6)",
      "text": "Row 1: Row Row 2: ...",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <Child-Pugh Child-Pugh A> (column column 6)",
      "text": "Row 1:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <treatments. treatments.>",
      "text": "Row 1: \"Clinical recommendation\" \"Row 2: \"Recommendation\" \"Recomendation\"\" Row 3: \"SIGN\" \"clinic\" \"Row 4: \"B\" \"Nei pz\" function function (Child-Pugh B\"), used. used.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <treatments. treatments.>",
      "text": "Row 1: \"Clinical recommendation\" \"Row 2: \"Recommendation\" \"Recomendation\"\" Row 3: \"SIGN\" \"clinical\" \"row\" 4: \"performed. performed.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <noc> (column column 8)",
      "text": "Row 1: Row Row 2: Row 3: id id isongaid",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "heading heading <isorriC> (column 9)",
      "text": "Row 1: Row 2:",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "heading heading <of of evidence: MODERATA>",
      "text": "cirrhosis cirrhosis (max Child-Pugh B) a a five-has has been: ==References===External links==* Official website* http://eu. eu.int/en/comm/index_en/compared. compared.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "heading heading <s s ) ) 8 2 MODATE>",
      "text": "==References===External links==* Official website",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "heading heading <for for AST>",
      "text": "==References===External links==* Official website",
      "start_page": 40,
      "end_page": 40
    }
  ]
}